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OBJECTIVE A systematic review was performed to provide objective evidence on the use of stereotactic radiosurgery 
(SRS) in the management of secretory pituitary adenomas and develop consensus recommendations.
METHODS The authors performed a systematic review of the English-language literature up until June 2018 using the 
PRISMA guidelines. The PubMed (Medline), Embase, and Cochrane databases were searched. A total of 45 articles 
reporting single-institution outcomes of SRS for acromegaly, Cushing’s disease, and prolactinomas were selected and 
included in the analysis.
RESULTS For acromegaly, random effects meta-analysis estimates for crude tumor control rate, crude endocrine 
remission rate, and any new hypopituitarism rates were 97.0% (95% CI 96.0%–98.0%), 44.0% (95% CI 35.0%–53.0%), 
and 17.0% (95% CI 13.0%–23.0%), respectively. For Cushing’s disease, random effects estimates for crude tumor con-
trol rate, crude endocrine remission rate, and any new hypopituitarism rate were 92.0% (95% CI 87.0%–95.0%), 48.0% 
(95% CI 35.0%–61.0%), and 21.0% (95% CI 13.0%–31.0%), respectively. For prolactinomas, random effects estimates 
for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate were 93.0% (95% CI 
90.0%–95.0%), 28.0% (95% CI 19.0%–39.0%), and 12.0% (95% CI 6.0%–24.0%), respectively. Meta-regression analysis 
did not show a statistically significant association between mean margin dose with crude endocrine remission rate or 
mean margin dose with development of any new hypopituitarism rate for any of the secretory subtypes.
CONCLUSIONS SRS offers effective tumor control of hormone-producing pituitary adenomas in the majority of patients 
but a lower rate of endocrine improvement or remission.
https://thejns.org/doi/abs/10.3171/2021.2.JNS204440
KEYWORDS acromegaly; Cushing’s disease; prolactinomas; secretory pituitary adenomas; pituitary surgery; 
stereotactic radiosurgery
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Pituitary adenomas (PAs) are common benign neo-plastic lesions arising from cells of the anterior pi-tuitary gland. Approximately 70% of PAs are asso-
ciated with hormonal hypersecretion syndromes, among 
which the most common are tumors secreting prolactin 
(PRL), growth hormone (GH), or adrenocorticotrophic 
hormone (ACTH).1 The management of secretory PA 
represents a significant challenge because of the need to 
adequately control hormonal hypersecretion in addition 
to tumor growth. Management options for secretory PA 
include medical therapy, surgical resection, and radia-
tion therapy (RT), alone or in combination. Stereotactic 
radiosurgery (SRS) is being increasingly used whenever 
possible as an alternative to fractionated RT, with the goal 
of limiting radiation exposure to adjacent normal tissues. 
However, the literature regarding the use of SRS in the 
treatment of PAs comprises only multiple retrospective 
studies. This study was performed under the International 
Stereotactic Radiosurgery Society (ISRS) guideline proj-
ect to systematize the available literature and develop 
consensus recommendations to guide the care of patients 
afflicted by the most common secretory subtypes: pro-




Using the PRISMA guidelines,2 a systematic review of 
the English-language literature up until June 2018 was per-
formed. The PubMed (Medline), Embase, and Cochrane 
databases were searched for relevant articles using the 
following MeSH terms: (Gamma Knife OR Radiosurgery 
OR LINAC OR CyberKnife) AND (pituitary adenoma 
OR Cushing’s disease OR acromegaly OR prolactinoma). 
The initial search provided 1045 articles whose titles and 
abstracts were screened for relevance, with 134 articles 
retained at this stage. Full-text screening was performed 
by using the following inclusion criteria: single-institution 
study, more than 10 patients reported, and both tumor and 
endocrine control data reported. Studies reporting the 
use of proton-based SRS or fractionated stereotactic RT 
and studies only reporting Nelson syndrome cases were 
excluded. In cases where multiple studies were from the 
same institution, only the most recent relevant publication 
with the most extensive data was included. After full-text 
screening, a total of 45 articles were selected for the fi-
nal analyses. All studies were retrospective and reported 
low-quality evidence. Many studies reported pooled out-
comes of all PAs treated at the reporting institution. From 
those, the data reporting the outcomes of Cushing’s dis-
ease, acromegaly, or prolactinoma were extracted, and the 
data were extracted separately for those three different 
subtypes. Separate analyses were performed for each se-
cretory subtype. The final review included 28 acromegaly 
studies, 13 Cushing’s disease studies, and 13 prolactinoma 
studies. Figure 1 describes the search strategy and inclu-
sion methodology as a PRISMA flow diagram.
Outcome Measures and Statistical Analyses
The primary outcomes of the study were endocrine re-
mission off medication and tumor control rates for each 
of the 3 main secretory subtypes. Endocrine and cranial 
nerve morbidity was also assessed. Data collection in-
cluded the number of cases per study, radiosurgery device 
used, mean follow-up time, prior resection, mean margin 
radiation dose and dose range, mean tumor volume, local 
control rate, endocrine remission and relapse rates, time 
to remission, criteria used for endocrine remission defini-
tion, predictors of endocrine response, new or worsening 
pituitary insufficiency rates, and new or worsening visual 
or cranial nerve morbidity.
Statistical analyses were performed using R Studio 
(version 1.1.423). Meta-analyses, tests for heterogeneity, 
analysis of publication bias, and meta-regressions were 
done with R package metafor (version 2.0-0). Study vari-
ances for the overall estimates and for meta-regression 
were calculated using the DerSimonian-Laird method. 
Weighted random effects models were used to calculate 
pooled estimates for crude rates of local control, endo-
crine remission rate, and new-onset hypopituitarism for 
each of the secretory subtypes. Given the study population 
variances across the studies, and since each study involves 
treatment decisions, the random effects model was consid-
ered superior to the fixed effects model when calculating 
pooled estimates. The I2 statistic was used for identifying 
heterogeneity: I2 values of 0%, 25%, 50%, and 75% were 
interpreted as indicating absent, low, moderate, and high 
heterogeneity, respectively. Funnel plots and the Egger 
test (p value < 0.05 indicating presence of bias) were used 
for identifying publication bias. Meta-regression analyses 
were performed to identify potential associations between 
endocrine remission rate or development of new-onset hy-
popituitarism and mean margin dose.
Results
Acromegaly
A total of 28 studies reporting acromegaly cases met 
inclusion criteria and were evaluated in the final analysis 
(Supplementary Table 1). All studies were retrospective 
and provided low-quality evidence. Selected articles were 
published between 1998 and 2018. The majority of studies 
reported patients treated by Gamma Knife radiosurgery 
(21 studies).3–23 CyberKnife was used in 2 studies,24,25 
linear accelerator (LINAC)–based SRS in 4 studies,26–29 
and a rotating gamma unit (MASEP) in 1 study.30 A to-
tal of 1335 patients were included in the meta-analysis. 
SRS was usually performed for recurrence or adjuvant 
treatment after tumor resection (65%–100% prior tumor 
resection in all except 2 studies). In single-fraction stud-
ies, mean margin doses reported ranged from 13.2 to 35 
Gy. Reported tumor control rates varied between 94% 
and 100%, and new neurological or visual deficit rates 
ranged between 0% and 11%. Crude endocrine remission 
rates varied between 0% and 82%. However, there was 
variability among studies relative to the criteria used to 
define endocrine cure. Only one study used the current 
consensus definition (GH level after an oral glucose tol-
erance test [OGTT] less than 0.4 ng/ml and normaliza-
tion of age- and sex-adjusted insulin-like growth factor–1 
[IGF-1] levels).31 The most common criteria to define re-
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mission were normalization of age- and sex-adjusted IGF-
1 levels and random GH values less than 2–2.5 ng/ml, 
used in 10 studies (35.7%). New or worsened hypopitu-
itarism was reported in 0%–40% of treated patients. The 
following factors were identified by some studies as being 
predictors of endocrine remission: GH and IGF-1 levels 
less than 2.25 times normal at time of SRS,5,8,14,17 absence 
of cavernous sinus invasion,8,11 male sex,11 higher margin 
dose,21 and absence of suppressive medication at SRS.14
Random effects meta-analyses for crude tumor control, 
crude endocrine remission, and any new hypopituitarism 
are shown in Figs. 2–4, with random effects estimates of 
97.0% (95% CI 96.0%–98.0%), 44.0% (95% CI 35.0%–
53.0%), and 17.0% (95% CI 13.0%–23.0%), respectively. 
Publication bias was assessed by using the Egger test. No 
evidence of publication bias was found for the studies in-
cluded for assessing crude tumor control rate (p = 0.251) 
and crude endocrine remission rate (p = 0.782). However, 
publication bias was evident for studies included for as-
sessing new hypopituitarism rate (p = 0.039). Funnel plots 
for publication bias are shown in Supplementary Fig. 1. 
Supplementary Fig. 2 shows meta-regression plots for 
association of mean margin dose with crude endocrine 
remission rate and any new hypopituitarism rate. Meta-
regression analysis did not show a statistically significant 
association between mean margin dose with crude endo-
crine remission rate (p = 0.054) and mean margin dose 
with any new hypopituitarism rate (p = 0.685).
Cushing’s Disease
A total of 13 studies reporting Cushing’s disease cases 
met inclusion criteria and were evaluated in the final anal-
ysis (Supplementary Table 2). All studies were retrospec-
tive and provided low-quality evidence. Selected articles 
were published between 1998 and 2018. Eight studies re-
ported patients treated by Gamma Knife radiosurgery,4,12, 
20, 32–36 whereas LINAC-based SRS was used in 4 stud-
ies29,37–39 and a rotating gamma unit (MASEP) in 1 study.30 
A total of 416 patients were included in the meta-analysis. 
SRS was usually performed for recurrence or adjuvant 
treatment after tumor resection (57%–100% prior tumor 
resection in all except 1 study). The mean margin dose 
reported ranged from 14.7 to 35 Gy. Reported tumor con-
trol rates varied between 83% and 100%, and new neuro-
logical or visual deficit rates ranged between 0% and 17%. 
Crude endocrine remission rates varied between 6% and 
81%. There was variability among studies relative to the 
criteria used to define endocrine cure, with the most com-
mon criteria used being normalization of 24-hour urinary 
FIG. 1. PRISMA flow diagram demonstrating the search strategy for study selection and inclusion in the systematic review for 
secretory PA SRS. Figure is available in color online only.
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free cortisol in 5 studies (38.5%). New or worsened hypo-
pituitarism was reported in 0%–50% of treated patients. 
The following factors were identified by some studies as 
being predictors of endocrine remission: smaller target 
volume,36 lower urinary cortisol level at SRS,33 and ab-
sence of suppressive medication at SRS.34,36
Random effects meta-analyses for crude tumor control, 
crude endocrine remission, and any new hypopituitarism 
are shown in Fig. 5, with random effects estimates of 
92.0% (95% CI 87.0%–95.0%), 48.0% (95% CI 35.0%–
61.0%), and 21.0% (95% CI 13.0%–31.0%), respectively. 
Publication bias was assessed by using the Egger test. No 
evidence of publication bias was found for the studies in-
cluded for assessing crude tumor control rate (p = 0.198) 
and crude endocrine remission rate (p = 0.524). However, 
publication bias was evident for studies included for as-
sessing new hypopituitarism rate (p = 0.023). Funnel plots 
for publication bias are shown in Supplementary Fig. 3. 
Supplementary Fig. 4 shows meta-regression plots for 
association of mean margin dose with crude endocrine 
remission rate and any new hypopituitarism rate. Meta-
regression analysis did not show a statistically significant 
association between mean margin dose with crude endo-
crine remission rate (p = 0.563) or mean margin dose with 
any new hypopituitarism rate (p = 0.952).
Prolactinomas
A total of 13 studies reporting prolactinoma cases met 
inclusion criteria and were evaluated in the final analysis 
(Supplementary Table 3). All studies were retrospective 
and provided low-quality evidence. Selected articles were 
published between 1998 and 2018. Nine studies reported 
patients treated by Gamma Knife radiosurgery,12,20, 22,40–45 
whereas LINAC-based SRS was used in 3 studies,29,46,47 
and a rotating gamma unit (MASEP) in 1 study.30 A total 
of 538 patients were included in the meta-analysis. SRS 
was performed after prior tumor resection in 2%–100% 
of cases for patients who had tumor growth and persis-
tent hyperprolactinemia on medical therapy, or who were 
FIG. 2. Forest plot for crude tumor control rate for acromegaly. Squares indicate the proportions from individual studies and 
horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight assigned in the pooled analysis 
using the random effects model. The diamond indicates the pooled proportion with 95% CI.
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intolerant to medication. The mean margin dose reported 
ranged from 13.5 to 35 Gy. Reported tumor control rates 
varied between 86% and 100%, and new neurological or 
visual deficit rates ranged between 0% and 5%. Crude 
endocrine remission rates varied between 6% and 81%. 
There was variability among studies relative to the criteria 
used to define endocrine cure, with most (8 studies, 61.5%) 
only stating normal PRL levels without specifying any 
numeral value or if patients needed to be off antisecre-
tory medication. New or worsened hypopituitarism was 
reported in 0%–62% of treated patients. The following 
factors were identified by some studies as being predictors 
of endocrine remission: tumor volume less than 3 ml,41 
PRL levels less than 200 µg/L,41 and margin dose more 
than 30 Gy.45 None of the included studies reported the use 
of a dopamine agonist at SRS as a significant predictor of 
endocrine outcome.
Random effects meta-analyses for crude tumor control, 
crude endocrine remission, and any new hypopituitarism 
are shown in Fig. 6, with random effects estimates of 
93.0% (95% CI 90.0%–95.0%), 28.0% (95% CI 19.0%–
39.0%), and 12.0% (95% CI 6.0%–24.0%), respectively. 
Publication bias was assessed by using the Egger test. No 
evidence of publication bias was found for the studies in-
cluded for assessing crude endocrine remission rate (p = 
0.783) and new hypopituitarism rate (p = 0.222). However, 
publication bias was evident for studies included for as-
sessing crude tumor control rate (p = 0.021). Funnel plots 
for publication bias are shown in Supplementary Fig. 5. 
Supplementary Fig. 6 shows meta-regression plots for 
association of mean margin dose with crude endocrine 
remission rate and any new hypopituitarism rate. Meta-
regression analysis did not show a statistically significant 
association of mean margin dose with crude endocrine 
remission rate (p = 0.699) or mean margin dose with any 
new hypopituitarism rate (p = 0.986).
FIG. 3. Forest plot for crude endocrine remission rate for acromegaly. Squares indicate the proportions from individual studies and 
horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight assigned in the pooled analysis 
using the random effects model. The diamond indicates the pooled proportion with 95% CI.
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Discussion
SRS is widely used in the management of PAs, both 
nonsecretory and secretory. An ISRS-performed system-
atic review of the literature and consensus guidelines for 
nonfunctioning adenomas (NFAs) of the pituitary have 
recently been published.48 Whereas the goal of treatment 
for NFAs is limited to tumor growth control, there is an 
additional challenge for secretory adenomas, namely con-
trol of the associated hypersecretory syndrome. For this 
systematic review, we selected 45 studies that reported the 
outcomes of SRS for patients with secretory PA. There are 
no prospective studies that have addressed this topic, to our 
knowledge, and most papers are single-center retrospective 
cohort studies and thus are evidence level IV studies. Nev-
ertheless, there are still significant findings to guide patient 
management and formulate recommendations (Table 1).
Tumor Growth Control
SRS has been mostly used in an adjuvant or recurrent 
setting after prior tumor resection. All tumor types seem 
to demonstrate excellent crude local tumor control after 
SRS. Based on our meta-analysis, tumor control at last 
follow-up can be expected in 97% of acromegaly patients, 
92% of Cushing’s disease patients, and 93% of prolacti-
noma patients. These rates are similar to those reported in 
NFA patients.48 However, there are a number of limitations 
that need to be taken into consideration when interpret-
ing these results. First, most studies reported only crude 
control rates, and not actuarial time-dependent control 
estimates. Long-term follow-up could reveal late tumor 
regrowth, thus lowering control rates. In addition, the ma-
jority of investigators did not differentiate between actu-
al tumor regression or stability in tumor size after SRS. 
While this might not make a difference from a strictly 
neuro-oncological point of view, this distinction remains 
important and should be reported in future studies to bet-
ter assess if tumor size variation after SRS has any impact 
on endocrine outcome. Finally, none of the investigators 
reported using volumetric evaluation for assessment of tu-
FIG. 4. Forest plot for any new hypopituitarism rate for acromegaly. Squares indicate the proportions from individual studies and 
horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight assigned in the pooled analysis 
using the random effects model. The diamond indicates the pooled proportion with 95% CI.
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FIG. 5. Forest plot for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate for Cushing’s disease. Squares 
indicate the proportions from individual studies and horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight 
assigned in the pooled analysis using the random effects model. The diamond indicates the pooled proportion with 95% CI. A: Forest plot for crude 
tumor control rate. B: Forest plot meta-analysis for crude endocrine remission rate. C: Forest plot for any new hypopituitarism rate.
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FIG. 6. Forest plot for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate for prolactinoma. Squares indicate the 
proportions from individual studies and horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight assigned in 
the pooled analysis using the random effects model. The diamond indicates the pooled proportion with 95% CI. A: Forest plot for crude tumor control 
rate. B: Forest plot meta-analysis for crude endocrine remission rate. C: Forest plot for any new hypopituitarism rate.
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mor size. Future studies should use 3D volumetric evalu-
ations to report change in tumor dimensions after SRS, 
ideally using standardized criteria such as RECIST (Re-
sponse Evaluation Criteria in Solid Tumours).
Endocrine Remission After SRS
The clinical presentation of secretory PA is most often 
related to the associated endocrinopathy rather than the 
compression of adjacent neural structures, and thus en-
docrine control is usually the main goal of management. 
Our meta-analysis confirms that SRS is more effective 
to control tumor growth than provide endocrine remis-
sion. Crude estimates for endocrine remission were 44% 
for acromegaly, 48% for Cushing’s disease, and 28% for 
prolactinomas. These data must be interpreted with cau-
tion. First, most studies report crude endocrine remission 
rates at last follow-up, and very few report actuarial rates 
at different intervals. The biological effect of SRS on hor-
monal hypersecretion is believed to act over time. There-
fore, crude rates might underestimate the true proportion 
of patients who will achieve remission after some latency 
period. For acromegaly, Pollock et al. reported cure rates 
of 11% at 2 years and 60% at 5 years after SRS.14 Similarly, 
Franzin et al. reported rates of 30.7%, 56.9%, and 80.4% 
after 3, 5, and 10 years, respectively.7 Lee et al. reported 
cure in 31.7% after 2 years, increasing to 64.5%, 73.4%, 
and 82.6% at 4, 6, and 8 years, respectively.5 Similar re-
sults were reported by Sheehan et al. in Cushing’s disease 
patients, with cure in 34% at 1 year, 54% at 2 years, 72% 
at 3 years, and 78% at 5 years after SRS.34 In addition, the 
analyzed literature spans a 20-year interval, during which 
there have been changes in the criteria used to define endo-
crine remission. As recommended by most endocrinology 
societies, those criteria have become more refined in the 
recent years. The Cortina consensus defined acromegaly 
remission as a random GH level less than 1 ng/ml or nadir 
GH after an OGTT less than 0.4 ng/ml and normalization 
of age- and sex-adjusted IGF-1 levels.49 The more recent 
acromegaly consensus conference dropped the random GH 
level requirement and only kept the other two criteria (na-
dir GH after OGTT and normalization of IGF-1 levels).31 
In this systematic review, only one of the selected studies 
used the more recent criteria to assess patients after SRS. 
In a series of 52 patients, Iwata et al.25 reported a crude 
cure rate of only 17%. Using the older Cortina consensus 
criteria, Sala et al.24 achieved a cure in 41% of 22 patients 
included in their study. In comparison, by using GH levels 
less than 2.5 ng/ml, Franzin et al.7 reported a cure rate of 
60.7% and Yan et al.27 obtained a cure in 68.2% of patients. 
The same variability in endocrine cure definition is seen in 
Cushing’s disease and prolactinoma studies. For Cushing’s 
disease, normal 24-hour urinary free cortisol has been the 
most frequent criterion used. Alternatively, many authors 
used serum cortisol or ACTH levels, alone or in combi-
nation with urinary levels. For prolactinomas, most study 
investigators used normal PRL levels to define remission 
without specifying normal value ranges. Using more se-
vere criteria will negatively impact cure rates, yet this is 
something that needs to be systematized moving forward.
Hypopituitarism After SRS
Among all included studies for all 3 secretory subtypes, 
new-onset or worsening of preexisting hypopituitarism 
was reported in 0%–50% of treated patients. Our meta-
analysis failed to identify any significant factor associ-
ated with an increase in new hormone deficiency risk. No 
article included in the meta-analysis has demonstrated a 
correlation between endocrine remission and hypopituita-
rism, and we also could not find any such relation with the 
pooled data. We also could not find any relation between 
the margin dose and the risk of hypopituitarism. However, 
this lack of association might be more related to the poor 
quality of the included studies than a real lack of effect. As 
is the case for endocrine remission reporting, there is wide 
heterogenicity in the way studies report hypopituitarism 
(clinical vs biochemical confirmation, lack of pre-SRS hy-
popituitarism mention, lack of individual axis evaluation). 
In addition, because most studies only report crude hypo-
TABLE 1. Recommendations for the use of SRS as part of the management of secretory PAs
Indications for SRS
 Effective option to control growth of GH-, ACTH-, & PRL-secreting residual or recurrent PAs after prior surgical resection but offers lower rate of 
endocrine improvement or remission.
 Could be used as primary therapy for GH- & ACTH-secreting PAs in patients deemed medically unfit for surgical resection.
 Could be used as alternative to surgical resection for PRL-secreting PAs unresponsive to dopaminergic agonists.
Prescription dose
 No minimal margin dose shown to definitively lead to better endocrine cure rates. Provided dose constraints safely protect surrounding structures 
at risk (optic pathways, brainstem); higher margin doses can be used, although added therapeutic benefits in terms of remission remain not fully 
defined.
SRS & use of antisecretory drugs
 Withdrawal of antisecretory medications preferred, typically for 4–12 wks prior to radiosurgery, if safely possible considering endocrinologic status 
of patient. Timing of temporary cessation of antisecretory medications & their reinstatement should be based on the particular agent pharmacology 
& patient’s ability to tolerate brief withdrawal of medical management.
Endocrine remission & tumor response criteria
 Investigators should report outcomes using most recently accepted consensus criteria for response, from perspectives of tumor volume & endo-
crine function.
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pituitarism rates, this likely leads to an underestimation of 
the risk, as the rate of new hormone deficiency is likely to 
increase over time.
Impact of the Prescription Dose
PAs are usually benign in histology, and as such, sin-
gle-fraction radiation doses of between 12 and 16 Gy have 
been demonstrated to provide durable control of tumor 
growth in NFA.48 This may also apply to hormone-secret-
ing tumors, as crude tumor control rates between 83% and 
100% have been reported across all 3 different studied 
subtypes, using median margin doses as low as 13–14 Gy 
in some studies.13,28 However, it has been widely believed 
that the doses required to stop the cellular mechanisms 
associated with hormonal hypersecretion are much high-
er than those required to control cellular division, and as 
such most authors have tried to deliver margin doses up to 
the range of 30–40 Gy, usually limited by the constraints 
of tumor volume and the proximity of optic apparatus. 
Despite this, only 2 of the selected studies actually found 
margin dose to be relevant for outcomes. In a study of 
68 acromegalic patients, Zhang et al. found better tumor 
control and resolution of hypertension and hyperglyce-
mia if margin doses were higher than 30 Gy.21 Pan et al. 
reported improved chances of hyperprolactinemia reso-
lution with margin doses of 30 Gy or more in 128 pro-
lactinoma patients.45 Our meta-regression analysis failed 
to demonstrate a relation between mean margin dose and 
crude endocrine remission rates for any of the 3 studies 
of tumor subtypes. However, this might only represent the 
fact that most authors have inherently used a dose selec-
tion threshold that is higher than the required one to pro-
duce an effect on hormone hypersecretion and might not 
be truly indicative of a lack of effect. In addition, regard-
ing dose selection, the concept of a biologically effective 
dose (BED) might be more important for outcomes than 
the absolute dose. In a recent study of the Mayo Clinic 
acromegaly series (not included in this meta-analysis), 
BED remained the only factor correlated with endocrine 
remission on multivariate analysis.50 Regarding morbid-
ity, we could not find any link between margin dose and 
the risk of pituitary function worsening among all tumor 
types, and the ophthalmological and neurological morbid-
ity was low in the majority of studies, despite the high 
margin dose used. None of the included studies reported 
that increasing margin dose led to higher risk of visual 
or neurological morbidity. Lee et al. used a dose of 25 
Gy in 136 acromegalic patients,5 with only 2.9% suffering 
from new visual field deficits and 0.7% new oculomotor 
palsy. Despite using 35 Gy, Jezková et al. did not report 
visual or neurological morbidity in 96 patients with acro-
megaly.16 Visual deterioration was reported in 11.1% of 71 
patients in Kobayashi’s acromegaly series, despite using 
a lower mean margin dose of 18.9 Gy.12 Based upon the 
available literature, if neuroanatomical dose constraints 
allow, higher margin doses could be utilized, although the 
added therapeutic benefit in terms of remission remains 
not fully defined.
Impact of Antisecretory Medication
The use of antisecretory drugs at the time of SRS is 
considered to negatively affect endocrine remission. For 
acromegaly, only the study by Pollock et al. confirmed 
this fact, with an HR of 4.2 of achieving remission when 
patients were off compared to on medication at SRS.14 
Alternatively, 3 studies did not find medication intake to 
impact cure rates.5,15,17 It is worth noting that for the most 
recent acromegaly studies, suppressive medications were 
stopped for 1 to 4 months before SRS in all patients, mak-
ing it difficult to confirm whether this is of importance 
or not.3,4, 24, 26,27 For prolactinomas, no study found a link 
between dopamine agonist intake and cure. Cohen-Inbar 
et al. reported that the use of a dopamine agonist at the 
time of SRS decreased cure rates from 50% in patients off 
medication to 38.1%, but the difference failed to reach sta-
tistical significance.40 Two other studies mentioned no dif-
ference in endocrine remission based on medication intake 
at SRS.41,43 The impact of antisecretory medication is even 
less clear for Cushing’s disease. The most common drug 
to control corticoid hypersecretion, ketoconazole, acts by 
decreasing peripheral cortisol synthesis at the adrenal lev-
el, although it might also reduce ACTH release from the 
anterior pituitary, as suggested by a preclinical study.51 In 
the study by Sheehan et al., patients who were off ketocon-
azole at SRS had faster time to endocrine remission than 
patients on medication, but the overall endocrine remission 
rates were no different.34 Conversely, Castinetti et al. found 
statistically significantly better cure rates in patients off 
ketoconazole at the time of SRS (48% vs 20%).36 Taking 
all into consideration, it appears reasonable to recommend 
withholding antisecretory medication for 4 to 12 weeks 
(depending on the individual drug’s pharmacokinetic pro-
file) before SRS in patients in whom the endocrine status 
is stable and temporary drug cessation is not expected to 
cause any harmful deterioration.
Timing of SRS in the Multimodality Management of 
Secretory PAs
The management of secretory PAs frequently neces-
sitates a combination of different modalities. SRS is usu-
ally viewed as a second or third-line option, after sur-
gical or medical management. This is reflected in our 
meta-analysis, whereas the majority of included studies 
of acromegaly or Cushing’s disease reported patients 
treated after surgical resection. Our results might not be 
applicable to patients who did not have prior resection. 
As such, we believe that patients who are deemed medi-
cally fit should be offered surgery as first-line manage-
ment if possible. However, there was more heterogenicity 
in the prior management of patients who were included in 
our prolactinoma analyses, reflecting the fact that prolac-
tinomas are exquisitely responsive to drug therapy, and 
surgery is rarely required for those patients. In addition, 
medically refractory prolactinomas tend to be more lo-
cally invasive, and surgery is generally deemed less likely 
to provide endocrine cure. In the study by Pan et al., only 
2.3% of patients had prior surgical resection.45 Similarly, 
Jezková et al. reported resection in only 28.6% of patients 
before SRS.43 SRS seems to be used more liberally as 
second-line therapy and might be more appropriately rec-
ommended in this setting for prolactinomas than GH- or 
ACTH-secreting tumors.
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Single-Fraction Versus Hypofractionated SRS
In this meta-analysis, we deliberately chose to exclude 
fractionated stereotactic radiation therapy (SRT) studies 
and focused on SRS studies. Since the literature is already 
heterogeneous with respect to single-fraction SRS, the in-
clusion of the limited number of fractionated SRT studies 
would only add confounding factors to our study. Taking 
into account the accepted ISRS-endorsed definition of 
SRS, 2 hypofractionated SRS acromegaly studies that oth-
erwise satisfied all inclusion criteria were included in the 
analysis.24,25 However, the results of those studies cannot 
be interpreted separately from the more prevalent single-
fraction studies, so extrapolations of equivalency must be 
made with caution.
Conclusions
SRS offers effective tumor control of hormone-produc-
ing PAs in the majority of patients but a lower rate of endo-
crine improvement or remission. However, the quality of 
evidence that can be extracted from the existing literature 
on SRS for secretory PAs is low, with most studies be-
ing single-center retrospective studies in design. Limited 
practice recommendations can be formulated based on 
the evidence, and those recommendations are applicable 
only to the secretory subtypes included in this study (GH-, 
ACTH-, and PRL-secreting tumors) and should not be ex-
trapolated to other histological subtypes.
Acknowledgments
We thank Prof. Frédéric Castinetti for his valuable comments 
on the manuscript.
References
 1. Daly AF, Beckers A. The epidemiology of pituitary adeno-
mas. Endocrinol Metab Clin North Am. 2020; 49(3): 347–355.
 2. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred 
reporting items for systematic reviews and meta-analyses: the 
PRISMA statement. J Clin Epidemiol. 2009; 62(10): 1006–1012.
 3. Kim EH, Oh MC, Chang JH, et al. Postoperative Gamma 
Knife radiosurgery for cavernous sinus-invading growth 
hormone-secreting pituitary adenomas. World Neurosurg. 
2018; 110: e534–e545.
 4. Grant RA, Whicker M, Lleva R, et al. Efficacy and safety of 
higher dose stereotactic radiosurgery for functional pituitary 
adenomas: a preliminary report. World Neurosurg. 2014; 82(1-
2): 195–201.
 5. Lee CC, Vance ML, Xu Z, et al. Stereotactic radiosurgery for 
acromegaly. J Clin Endocrinol Metab. 2014; 99(4): 1273–1281.
 6. Zeiler FA, Bigder M, Kaufmann A, et al. Gamma knife in the 
treatment of pituitary adenomas: results of a single center. 
Can J Neurol Sci. 2013; 40(4): 546–552.
 7. Franzin A, Spatola G, Losa M, et al. Results of gamma knife 
radiosurgery in acromegaly. Int J Endocrinol. 2012; 2012: 
342034.
 8. Liu X, Kano H, Kondziolka D, et al. Gamma knife radiosur-
gery for clinically persistent acromegaly. J Neurooncol. 2012; 
109(1): 71–79.
 9. Castro DG, Cecílio SAJ, Canteras MM. Radiosurgery for pi-
tuitary adenomas: evaluation of its efficacy and safety. Radiat 
Oncol. 2010; 5: 109.
10. Iwai Y, Yamanaka K, Yoshimura M, et al. Gamma knife ra-
diosurgery for growth hormone-producing adenomas. J Clin 
Neurosci. 2010; 17(3): 299–304.
11. Poon TL, Leung SCL, Poon CYF, Yu CP. Predictors of 
outcome following Gamma Knife surgery for acromegaly. J 
Neurosurg. 2010; 113(suppl): 149–152.
12. Kobayashi T. Long-term results of stereotactic gamma knife 
radiosurgery for pituitary adenomas. Specific strategies for 
different types of adenoma. Prog Neurol Surg. 2009; 22: 77–95.
13. Swords FM, Monson JP, Besser GM, et al. Gamma knife 
radiosurgery: a safe and effective salvage treatment for 
pituitary tumours not controlled despite conventional radio-
therapy. Eur J Endocrinol. 2009; 161(6): 819–828.
14. Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery 
of growth hormone-producing pituitary adenomas: factors 
associated with biochemical remission. J Neurosurg. 2007; 
106(5): 833–838.
15. Vik-Mo EO, Oksnes M, Pedersen PH, et al. Gamma knife 
stereotactic radiosurgery for acromegaly. Eur J Endocrinol. 
2007; 157(3): 255–263.
16. Jezková J, Marek J, Hána V, et al. Gamma knife radiosurgery 
for acromegaly—long-term experience. Clin Endocrinol 
(Oxf). 2006; 64(5): 588–595.
17. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma 
knife radiosurgery in 82 patients with acromegaly: correla-
tion with initial hypersecretion. J Clin Endocrinol Metab. 
2005; 90(8): 4483–4488.
18. Gutt B, Wowra B, Alexandrov R, et al. Gamma-knife surgery 
is effective in normalising plasma insulin-like growth factor 
I in patients with acromegaly. Exp Clin Endocrinol Diabetes. 
2005; 113(4): 219–224.
19. Ikeda H, Jokura H, Yoshimoto T. Transsphenoidal surgery 
and adjuvant gamma knife treatment for growth hormone-se-
creting pituitary adenoma. J Neurosurg. 2001; 95(2): 285–291.
20. Izawa M, Hayashi M, Nakaya K, et al. Gamma knife radio-
surgery for pituitary adenomas. J Neurosurg. 2000; 93(suppl 
3): 19–22.
21. Zhang N, Pan L, Wang EM, et al. Radiosurgery for growth 
hormone-producing pituitary adenomas. J Neurosurg. 2000; 
93(suppl 3): 6–9.
22. Mokry M, Ramschak-Schwarzer S, Simbrunner J, et al. A six 
year experience with the postoperative radiosurgical manage-
ment of pituitary adenomas. Stereotact Funct Neurosurg. 
1999; 72 Suppl 1(1): 88–100.
23. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosur-
gery for recurrent surgically treated acromegaly: comparison 
with fractionated radiotherapy. J Neurosurg. 1998; 88(6): 
1002–1008.
24. Sala E, Moore JM, Amorin A, et al. CyberKnife robotic 
radiosurgery in the multimodal management of acromegaly 
patients with invasive macroadenoma: a single center’s expe-
rience. J Neurooncol. 2018; 138(2): 291–298.
25. Iwata H, Sato K, Nomura R, et al. Long-term results of hy-
pofractionated stereotactic radiotherapy with CyberKnife for 
growth hormone-secreting pituitary adenoma: evaluation by 
the Cortina consensus. J Neurooncol. 2016; 128(2): 267–275.
26. Wilson PJ, De-Loyde KJ, Williams JR, Smee RI. Acromeg-
aly: a single centre’s experience of stereotactic radiosurgery 
and radiotherapy for growth hormone secreting pituitary 
tumours with the linear accelerator. J Clin Neurosci. 2013; 
20(11): 1506–1513.
27. Yan JL, Chang CN, Chuang CC, et al. Long-term follow-up 
of patients with surgical intractable acromegaly after linear 
accelerator radiosurgery. J Formos Med Assoc. 2013; 112(7): 
416–420.
28. Sallabanda K, Usychkin S, Puebla F, et al. Stereotactic radio-
surgery in pituitary adenomas: long-term single institution 
experience and role of the hypothalamic-pituitary axis. J 
Radiosurg SBRT. 2011; 1(3): 213–220.
29. Voges J, Kocher M, Runge M, et al. Linear accelerator 
radiosurgery for pituitary macroadenomas: a 7-year follow-up 
study. Cancer. 2006; 107(6): 1355–1364.
Unauthenticated | Downloaded 09/17/21 01:32 PM UTC
Mathieu et al.
J Neurosurg September 3, 202112
30. Wan H, Chihiro O, Yuan S. MASEP gamma knife radio-
surgery for secretory pituitary adenomas: experience in 347 
consecutive cases. J Exp Clin Cancer Res. 2009; 28: 36.
31. Melmed S, Bronstein MD, Chanson P, et al. A Consensus 
Statement on acromegaly therapeutic outcomes. Nat Rev 
Endocrinol. 2018; 14(9): 552–561.
32. Narayan V, Mohammed N, Bir SC, et al. Long-term outcome 
of nonfunctioning and hormonal active pituitary adenoma 
after Gamma Knife radiosurgery. World Neurosurg. 2018; 
114: e824–e832.
33. Marek J, Ježková J, Hána V, et al. Gamma knife radiosurgery 
for Cushing’s disease and Nelson’s syndrome. Pituitary. 
2015; 18(3): 376–384.
34. Sheehan JP, Xu Z, Salvetti DJ, et al. Results of Gamma Knife 
surgery for Cushing’s disease. J Neurosurg. 2013; 119(6): 
1486–1492.
35. Tinnel BA, Henderson MA, Witt TC, et al. Endocrine re-
sponse after Gamma Knife-based stereotactic radiosurgery 
for secretory pituitary adenoma. Stereotact Funct Neurosurg. 
2008; 86(5): 292–296.
36. Castinetti F, Nagai M, Dufour H, et al. Gamma knife radio-
surgery is a successful adjunctive treatment in Cushing’s 
disease. Eur J Endocrinol. 2007; 156(1): 91–98.
37. Wilson PJ, Williams JR, Smee RI. Cushing’s disease: a single 
centre’s experience using the linear accelerator (LINAC) for 
stereotactic radiosurgery and fractionated stereotactic radio-
therapy. J Clin Neurosci. 2014; 21(1): 100–106.
38. Wein L, Dally M, Bach LA. Stereotactic radiosurgery for 
treatment of Cushing disease: an Australian experience. 
Intern Med J. 2012; 42(10): 1153–1156.
39. Devin JK, Allen GS, Cmelak AJ, et al. The efficacy of linear 
accelerator radiosurgery in the management of patients with 
Cushing’s disease. Stereotact Funct Neurosurg. 2004; 82(5-6): 
254–262.
40. Cohen-Inbar O, Xu Z, Schlesinger D, et al. Gamma Knife 
radiosurgery for medically and surgically refractory prolacti-
nomas: long-term results. Pituitary. 2015; 18(6): 820–830.
41. Liu X, Kano H, Kondziolka D, et al. Gamma knife stereo-
tactic radiosurgery for drug resistant or intolerant invasive 
prolactinomas. Pituitary. 2013; 16(1): 68–75.
42. Tanaka S, Link MJ, Brown PD, et al. Gamma knife radiosur-
gery for patients with prolactin-secreting pituitary adenomas. 
World Neurosurg. 2010; 74(1): 147–152.
43. Jezková J, Hána V, Krsek M, et al. Use of the Leksell gamma 
knife in the treatment of prolactinoma patients. Clin Endocri-
nol (Oxf). 2009; 70(5): 732–741.
44. Petrovich Z, Yu C, Giannotta SL, et al. Gamma knife radio-
surgery for pituitary adenoma: early results. Neurosurgery. 
2003; 53(1): 51–61.
45. Pan L, Zhang N, Wang EM, et al. Gamma knife radiosurgery 
as a primary treatment for prolactinomas. J Neurosurg. 2000; 
93(suppl 3): 10–13.
46. Wilson PJ, Williams JR, Smee RI. Single-centre experience 
of stereotactic radiosurgery and fractionated stereotactic 
radiotherapy for prolactinomas with the linear accelerator. J 
Med Imaging Radiat Oncol. 2015; 59(3): 371–378.
47. Yoon SC, Suh TS, Jang HS, et al. Clinical results of 24 pitu-
itary macroadenomas with linac-based stereotactic radiosur-
gery. Int J Radiat Oncol Biol Phys. 1998; 41(4): 849–853.
48. Kotecha R, Sahgal A, Rubens M, et al. Stereotactic radiosur-
gery for non-functioning pituitary adenomas: meta-analysis 
and International Stereotactic Radiosurgery Society practice 
opinion. Neuro Oncol. 2020; 22(3): 318–332.
49. Giustina A, Chanson P, Bronstein MD, et al. A consensus 
on criteria for cure of acromegaly. J Clin Endocrinol Metab. 
2010; 95(7): 3141–3148.
50. Graffeo CS, Donegan D, Erickson D, et al. The impact of in-
sulin-like growth factor index and biologically effective dose 
on outcomes after stereotactic radiosurgery for acromegaly: 
cohort study. Neurosurgery. 2020; 87(3): 538–546.
51. Stalla GK, Stalla J, Loeffler JP, et al. Pharmacological modu-
lation of CRH-stimulated ACTH secretion by ketoconazole. 
Horm Metab Res Suppl. 1987; 16: 31–36.
Disclaimer
These guidelines should not be considered inclusive of all meth-
ods of care or exclusive of other methods or care reasonably 
directed to obtain similar results. The physician must make the 
ultimate judgment depending on characteristics and circum-
stances of individual patients. Adherence to this guideline will 
not ensure successful treatment in every situation. The authors 
of this guideline and the International Society of Stereotactic 
Radiosurgery assume no liability for the information, conclusions, 
and recommendations contained in this report. 
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